Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce F Liu

Showing results (11-20 of 105) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancerJoyce F Liu, Stephen A Cannistra
Cancer|April 15, 2023
One fixed dosing of a poly(adenosine diphosphate ribose) polymerase inhibitor does not fit allJung-Min Lee, Joyce F Liu
Cancer|April 7, 2025
Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancerMelissa K Frey, Joyce F Liu
The New England Journal of Medicine|February 18, 2005
Interns' work hoursNathan A Pennell, Joyce F Liu, Michael J Mazzini
Cancer|July 3, 2026
Maintenance therapy in gynecologic malignancies: Current and future statePage C Widick, Alexi A Wright, Joyce F Liu
Gynecologic Oncology|March 11, 2014
PARP inhibitors in ovarian cancer: current status and future promiseJoyce F Liu, Panagiotis A Konstantinopoulos, Ursula A Matulonis
Cultural Diversity & Ethnic Minority Psychology|July 30, 2002
Asian American-white American differences in expressions of social anxiety: a replication and extensionSumie Okazaki, Joyce F Liu, Sandra L Longworth, et al.
Gynecologic Oncology|October 3, 2009
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinomaJoyce F Liu, Michelle S Hirsch, Hang Lee, et al.
Gynecologic Oncology|November 8, 2020
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapiesElizabeth K Lee, Amanda N Fader, Alessandro D Santin, et al.
Gynecologic Oncology|October 22, 2019
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutationsJennifer Taylor Veneris, Ursula A Matulonis, Joyce F Liu, et al.
Pageof 11

Showing results (11-20 of 105) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancerJoyce F Liu, Stephen A Cannistra
Cancer|April 15, 2023
One fixed dosing of a poly(adenosine diphosphate ribose) polymerase inhibitor does not fit allJung-Min Lee, Joyce F Liu
Cancer|April 7, 2025
Shedding LIGHT on the changing landscape of poly-ADP ribose polymerase inhibitors in ovarian cancerMelissa K Frey, Joyce F Liu
The New England Journal of Medicine|February 18, 2005
Interns' work hoursNathan A Pennell, Joyce F Liu, Michael J Mazzini
Cancer|July 3, 2026
Maintenance therapy in gynecologic malignancies: Current and future statePage C Widick, Alexi A Wright, Joyce F Liu
Gynecologic Oncology|March 11, 2014
PARP inhibitors in ovarian cancer: current status and future promiseJoyce F Liu, Panagiotis A Konstantinopoulos, Ursula A Matulonis
Cultural Diversity & Ethnic Minority Psychology|July 30, 2002
Asian American-white American differences in expressions of social anxiety: a replication and extensionSumie Okazaki, Joyce F Liu, Sandra L Longworth, et al.
Gynecologic Oncology|October 3, 2009
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinomaJoyce F Liu, Michelle S Hirsch, Hang Lee, et al.
Gynecologic Oncology|November 8, 2020
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapiesElizabeth K Lee, Amanda N Fader, Alessandro D Santin, et al.
Gynecologic Oncology|October 22, 2019
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutationsJennifer Taylor Veneris, Ursula A Matulonis, Joyce F Liu, et al.
Pageof 11